Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.

Abstract

BACKGROUND:

The production of oxidative stress as a result of postprandial hyperglycaemia is now recognized as an important contributing factor in the development of diabetes complications. The objective of this study was to examine the effects of pramlintide on plasma concentrations of glucose and several markers of oxidative stress in patients with type 2 diabetes following a standardized meal.

METHODS:

This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States. A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study. Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days. Plasma concentrations of glucose, nitrotyrosine (NT), oxidized-LDL cholesterol (OxLDL-C), and total radical trapping parameter (TRAP) were assessed during the 4-h postprandial period.

RESULTS:

Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption. Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.

CONCLUSIONS:

The reduction in postprandial glucose excursions achieved with addition of pramlintide to rapid-acting insulin in type 2 diabetes was associated with a reduction in postprandial markers of oxidative stress.

• Authors: Antonio Ceriello, Cameron W Lush, Tamara Darsow, Ludovica Piconi, Maddelena Corgnali, Nuwan Nanayakkara, Juan P Frias, David Maggs
• Journal: Diabetes/metabolism research and reviews (Diabetes Metab Res Rev) Vol. 24 Issue 2 Pg. 103-8 (Feb 2008) ISSN: 1520-7552 [Print] England
• PMID: 17694505 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Copyright (c) 2007 John Wiley & Sons, Ltd.

Chemical References

• Amyloid
• Biomarkers
• Blood Glucose
• Cholesterol, LDL
• Insulin
• Insulin Lispro
• Islet Amyloid Polypeptide
• 3-nitrotyrosine
• Tyrosine
• pramlintide

Topics

• Adolescent
• Adult
• Amyloid (adverse effects, therapeutic use)
• Biomarkers (blood)
• Blood Glucose (drug effects, metabolism)
• Cholesterol, LDL (blood)
• Diabetes Mellitus, Type 2 (drug therapy, physiopathology)
• Female
• Humans
• Insulin (analogs & derivatives, therapeutic use)
• Insulin Lispro
• Islet Amyloid Polypeptide
• Male
• Middle Aged
• Oxidative Stress (drug effects)
• Postprandial Period (physiology)
• Single-Blind Method
• Tyrosine (analogs & derivatives, blood)